A phase 1 trial of an adenoviral vector carrying the wild-type p53 gene (Ad-p53) demonstrated that Ad-p53 successfully transfected astrocytic tumor cells with minimal toxicity when intratumorally injected pre- and post-resection of the glioma tumor; however, transfected cells were only detected on average within 5 mm of the injection site [53], demonstrating the limited ability of the therapeutic to penetrate the tumor tissue. The gene discussed is TP53; the disease is glioma.